TY - JOUR
T1 - Prostate cancer, version 1.2016
T2 - Featured updates to the NCCN guidelines
AU - Mohler, James L.
AU - Armstrong, Andrew J.
AU - Bahnson, Robert R.
AU - D'Amico, Anthony Victor
AU - Davis, Brian J.
AU - Eastham, James A.
AU - Enke, Charles A.
AU - Farrington, Thomas A.
AU - Higano, Celestia S.
AU - Horwitz, Eric M.
AU - Hurwitz, Michael
AU - Kane, Christopher J.
AU - Kawachi, Mark H.
AU - Kuettel, Michael
AU - Lee, Richard J.
AU - Meeks, Joshua J.
AU - Penson, David F.
AU - Plimack, Elizabeth R.
AU - Pow-Sang, Julio M.
AU - Raben, David
AU - Richey, Sylvia
AU - Roach, Mack
AU - Rosenfeld, Stan
AU - Schaeffer, Edward
AU - Skolarus, Ted A.
AU - Small, Eric J.
AU - Sonpavde, Guru
AU - Srinivas, Sandy
AU - Strope, Seth A.
AU - Tward, Jonathan
AU - Shead, Dorothy A.
AU - Freedman-Cass, Deborah A.
N1 - Publisher Copyright:
© 2016 JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
AB - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
UR - http://www.scopus.com/inward/record.url?scp=84969516736&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000367629000005&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2016.0004
DO - 10.6004/jnccn.2016.0004
M3 - Article
C2 - 26733552
SN - 1540-1405
VL - 14
SP - 19
EP - 30
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 1
ER -